SK-MEL-29.1 Cells

SK-MEL-29.1 is a melanoma cell line that has been extensively studied for its interactions with the immune system, particularly in the context of cytotoxic T-lymphocyte (CTL) recognition. This subclone of the SK-MEL-29 melanoma line has been used in immunological research to define specific antigens recognized by autologous CTLs. These CTLs selectively target melanoma cells expressing certain antigens, while sparing non-cancerous cells. In immunoselection experiments, SK-MEL-29.1 was found to express stable antigens that are important for the specific lysis of melanoma cells by CTLs, providing insights into tumor immunogenicity and immune evasion.
One of the key studies involving SK-MEL-29.1 demonstrated its utility in cancer immunotherapy research. CTL clones derived from patient AV were shown to effectively target SK-MEL-29.1 cells, which express multiple antigens simultaneously. This makes SK-MEL-29.1 an important model for understanding how immune responses can be tailored to target specific antigens in melanoma. The ability of these CTL clones to identify and lyse melanoma cells provides valuable information for the development of immunotherapeutic strategies, including the possibility of generating personalized cancer vaccines.
Furthermore, SK-MEL-29.1 cells have also been tested in virus-based cancer vaccine development. Infection with the Newcastle disease virus (NDV), a virus with oncolytic and immune-stimulatory properties, demonstrated that SK-MEL-29.1 can be efficiently infected by NDV even after gamma-irradiation, making it a suitable candidate for the development of live cancer vaccines. This infection enhances the immunogenicity of the tumor cells, leading to a more robust anti-tumor immune response, further supporting the use of SK-MEL-29.1 in vaccine research.